CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is projected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.14) per share and revenue of $4.6820 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. On average, analysts expect CytomX Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX traded down $0.02 during midday trading on Tuesday, hitting $4.16. 361,270 shares of the company’s stock were exchanged, compared to its average volume of 5,830,027. The stock has a 50 day moving average price of $4.74 and a 200-day moving average price of $4.51. The company has a market cap of $707.98 million, a PE ratio of -104.43 and a beta of 2.18. CytomX Therapeutics has a 12 month low of $0.90 and a 12 month high of $8.21.

Insider Activity

In other CytomX Therapeutics news, SVP Marcia Belvin sold 31,492 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $202,178.64. Following the completion of the sale, the senior vice president directly owned 300,760 shares of the company’s stock, valued at $1,930,879.20. The trade was a 9.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher Ogden sold 19,323 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the transaction, the chief financial officer owned 296,948 shares in the company, valued at approximately $1,906,406.16. The trade was a 6.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 191,063 shares of company stock valued at $1,226,624. 6.60% of the stock is currently owned by corporate insiders.

Institutional Trading of CytomX Therapeutics

Institutional investors have recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new stake in CytomX Therapeutics in the second quarter valued at $19,208,000. Commodore Capital LP acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $17,462,000. Perceptive Advisors LLC purchased a new position in CytomX Therapeutics during the 2nd quarter worth approximately $15,876,000. State Street Corp boosted its holdings in shares of CytomX Therapeutics by 697.1% in the fourth quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 4,495,949 shares during the period. Finally, ADAR1 Capital Management LLC grew its position in shares of CytomX Therapeutics by 31.3% during the third quarter. ADAR1 Capital Management LLC now owns 4,045,414 shares of the biotechnology company’s stock worth $12,905,000 after acquiring an additional 964,000 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

CTMX has been the subject of a number of research reports. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $7.00 to $12.00 in a report on Monday, March 16th. Wedbush upped their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research note on Monday, March 16th. Barclays raised their target price on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Finally, Guggenheim increased their price objective on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.44.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.